Search Results for: CRISPR for sickle cell disease

The Hope of CRISPRcon: Year 2, Guest Post by Anna Everette

Anna-Everette

By Anna Everette The title of this article is partially borrowed from a fascinating Lightning Presentation delivered by John Doench of Broad Institute at CRISPRcon this year. In his talk, Mr. Doench pointed out how we’ve been looking up to this promising technology for a while now, hoping it will deliver the anticipated results (see

The Hope of CRISPRcon: Year 2, Guest Post by Anna Everette Read More »

Weekend reads: stem cells, organoids, cancer, CRISPR & a tiger named Igor

Tiger

What are your typical weekend reads? If you are a scientist, they might often include a great deal of science. I always hope I can find time for reading for pleasure too, but about as close as I get to that is the New York Times on Sunday. Here are some recommended science reads for

Weekend reads: stem cells, organoids, cancer, CRISPR & a tiger named Igor Read More »

Countering that Pro-Heritable Human CRISPR WSJ Piece

human-embryo-modification

It’s germline, heritable human CRISPR time, right? Wrong. But the particularly enthusiastic supporters of heritable human CRISPR often cite hypothetical benefits in glowing terms, but either don’t mention risks or strongly downplay them. These fans also tend to leave alternative, proven and safe technologies such as preimplantation genetic diagnosis (PGD) out of the discussion or

Countering that Pro-Heritable Human CRISPR WSJ Piece Read More »

Weekly reads: clonal expansion, Golden Retriever cancer, FTC hits genetics firm on testi-phony-als

clonal selection

Let’s start this week’s digest with a discussion of clonal expansion and mutations during cell and gene therapy development. Here’s the article that brought this to mind. Sickle cell gene therapy process may cause cancer-linked mutations in blood stem cells, Fierce Biotech. Clonal expansion This is a story about a non-CRISPR gene therapy using a

Weekly reads: clonal expansion, Golden Retriever cancer, FTC hits genetics firm on testi-phony-als Read More »

Weekly reads: Verve Therapeutics, Casgevy UK OK, GDNF, MYC

Sekar Kathiresan, Verve Therapeutics

Some folks can view data from early, small clinical trials too skeptically or overly enthusiastically, and maybe that’s going on with some preliminary results from Verve Therapeutics. Good news? Bad news? I’m going to start with two articles about the same news that have very different vibes. What do I think? On the whole, I

Weekly reads: Verve Therapeutics, Casgevy UK OK, GDNF, MYC Read More »

Live blogging Future of Genome Medicine: great talks by Feng Zhang & others

Feng-Zhang-talk-e1488664593428

What is the future of Genome Medicine? The meeting by that same name that I’m at down here in La Jolla is all about tackling this question and the line up of speakers today on the first day is amazing. I’m speaking about IPS cells as a basis for personalized medicine tomorrow morning so that’s exciting.

Live blogging Future of Genome Medicine: great talks by Feng Zhang & others Read More »